Seaport Therapeutics, Inc. (SPTX) Financial Statements

15 Followers

Seaport Therapeutics, Inc. Financial Overview

Seaport Therapeutics, Inc.'s market cap is currently $1.16B. The company's EPS TTM is $; its P/E ratio is -10.88; Seaport Therapeutics, Inc. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25
Income Statement
Total Revenue	$ 0.00
Gross Profit	$ 0.00
Operating Income	$ -87.29M
EBITDA	$ -85.89M
Net Income	$ -74.88M
Balance Sheet
Cash & Short-Term Investments	$ 215.98M
Total Assets	$ 249.01M
Total Debt	$ 5.08M
Net Debt	$ -40.96M
Total Liabilities	$ 341.55M
Stockholders' Equity	$ -92.55M
Cash Flow
Free Cash Flow	$ -78.30M
Operating Cash Flow	$ -77.94M
Investing Cash Flow	$ -184.25M
Financing Cash Flow	$ -873.00K

Currency in USD

Seaport Therapeutics, Inc. Earnings and Revenue History

Income Statement >

Seaport Therapeutics, Inc. Debt to Assets

Balance Sheet >

Seaport Therapeutics, Inc. Cash Flow

Cash Flow >

Seaport Therapeutics, Inc. Forecast EPS vs Actual EPS

Earnings >